PLSE Key Statistics, Chart & Performance
The current stock price of PLSE is 13.71 USD. In the past month the price increased by 2.39%. In the past year, price decreased by -37.05%.
PLSE Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to PLSE. When comparing the yearly performance of all stocks, PLSE is a bad performer in the overall market: 87.68% of all stocks are doing better.
PLSE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PLSE. While PLSE has a great health rating, there are worries on its profitability.
PLSE Financial Highlights
Over the last trailing twelve months PLSE reported a non-GAAP Earnings per Share(EPS) of -0.83. The EPS decreased by -40.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -68.71% | ||
| ROE | -80.62% | ||
| Debt/Equity | 0 |
PLSE Forecast & Estimates
7 analysts have analysed PLSE and the average price target is 22.44 USD. This implies a price increase of 63.68% is expected in the next year compared to the current price of 13.71.
PLSE Ownership
About PLSE
Company Profile
Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. The company is headquartered in Hayward, California and currently employs 75 full-time employees. The company went IPO on 2016-05-18. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The company is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Its nsPFA Percutaneous Electrode System consists of a disposable, percutaneous, needle electrode for use with its CellFX Console. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. The company is also developing a Nanosecond PFA 360-degree Cardiac Catheter System.
Company Info
PULSE BIOSCIENCES INC
3957 Point Eden Way
Hayward CALIFORNIA 94545 US
CEO: Darrin R. Uecker
Employees: 75
Phone: 15109064600
PULSE BIOSCIENCES INC / PLSE FAQ
What does PLSE do?
Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. The company is headquartered in Hayward, California and currently employs 75 full-time employees. The company went IPO on 2016-05-18. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The company is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Its nsPFA Percutaneous Electrode System consists of a disposable, percutaneous, needle electrode for use with its CellFX Console. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. The company is also developing a Nanosecond PFA 360-degree Cardiac Catheter System.
What is the current price of PLSE stock?
The current stock price of PLSE is 13.71 USD. The price decreased by -0.87% in the last trading session.
Does PULSE BIOSCIENCES INC pay dividends?
PLSE does not pay a dividend.
What is the ChartMill rating of PULSE BIOSCIENCES INC stock?
PLSE has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the upcoming earnings date for PULSE BIOSCIENCES INC?
PULSE BIOSCIENCES INC (PLSE) will report earnings on 2026-03-25.
Can you provide the short interest for PLSE stock?
The outstanding short interest for PULSE BIOSCIENCES INC (PLSE) is 15.11% of its float.